Drug combination targeting HSP90 and BRAF is safe and effective in advanced melanoma

(H. Lee Moffitt Cancer Center& Research Institute) A team of researchers at Moffitt Cancer Center have been working to learn more about how melanoma becomes resistant to BRAF inhibitors in order to develop new treatment strategies. They tested whether a drug targeting heat shock protein 90 (HSP90) combined with the BRAF inhibitor vemurafenib could be a safe and potentially effective strategy to treat patients with melanoma. Their study was published online ahead of print in Clinical Cancer Research.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news